Goldman Sachs Group »

Enliven Therapeutics shares owned by Goldman Sachs Group

Quarter-by-quarter ownership of Enliven Therapeutics (ELVN) shares owned by Goldman Sachs Group from 13F filings

Historical chart of Goldman Sachs Group investment in Enliven Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Enliven Therapeutics held by Goldman Sachs Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Enliven Therapeutics by Goldman Sachs Group

Quarter filed Position value Share count Share price at filing
2023-12-31 $314k 23k 13.84
2023-09-30 $242k 18k 13.66
2023-06-30 $557k 27k 20.41
2023-03-31 $907k 41k 21.90